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Abstract 
Background: Treatment of clinical Plasmodium falciparum malaria with sulfadoxine‑pyrimethamine (SP) and amodi‑
aquine (AQ) is associated with increased post‑treatment gametocyte carriage. The effect of seasonal malaria chemo‑
prevention (SMC) with SP and AQ on gametocyte carriage was assessed in asymptomatic P. falciparum infected 
children.
Methods: The study was carried out in eastern Gambia. Asymptomatic P. falciparum malaria infected children aged 
24–59 months old who were eligible to receive SMC (SMC group) and children 5–8 years that were not eligible to 
receive SMC (comparison group) were recruited. Gametocytaemia was determined by molecular methods before and 
after SMC administration. Gametocyte carriage between the groups was compared using the chi‑squared test and 
within‑person using conditional logistic regression.
Results: During the 2017 and 2018 malaria transmission seasons, 65 and 75 children were recruited in the SMC and 
comparison groups, respectively. Before SMC administration, gametocyte prevalence was 10.7% (7/65) in the SMC 
group and 13.3% (10/75) in the comparison group (p = 0.64). At day 13 (IQR 12, 13) after SMC administration, this 
was 9.4% (5/53) in children who received at least the first dose of SMC treatment and 12.7% (9/71) for those in the 
comparison group (p = 0.57). Similarly, there was no difference in prevalence of gametocytes between children that 
adhered to all 3‑day doses of SMC treatment 15.6% (5/32) and those in the comparison group (p = 0.68). In the SMC 
group, within‑group gametocyte carriage was similar before and after SMC administration in children that received at 
least the first dose of SMC treatment (OR 0.6, 95% CI 0.14–2.51; p = 0.48) and in those that adhered to all 3‑day doses 
of SMC treatment (OR 1.0, 95% CI 0.20–4.95; p = 1.0).
Conclusion: In this study with relative low gametocyte prevalence prior to SMC treatment, no evidence was 
observed that SMC treatment increased gametocyte carriage in asymptomatic P. falciparum malaria infected children.
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Background
The global malaria burden has substantially reduced 
over the last two decades owing to the scale up of con-
trol interventions [1, 2]. In sub-Saharan Africa, Plas-
modium falciparum is the predominant malaria species 
and remains the focus of control and elimination efforts 
[2]. Since 2012, the World Health Organization (WHO) 
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recommends seasonal malaria chemoprevention (SMC) 
as an additional tool for malaria control where trans-
mission is highly seasonal, primarily the Sahel region of 
sub-Saharan Africa [3]. SMC is the monthly administra-
tion of a full course of sulfadoxine-pyrimethamine (SP) 
and amodiaquine (AQ) to all children 3–59  months 
old during the 3–4 months of the malaria transmission 
season regardless of infection status with the goal of 
reducing malaria morbidity and mortality.
Given that many P. falciparum infections are asymp-
tomatic in both high and low transmission settings [4, 
5] and can persist for long periods of time [4, 6, 7], the 
systematic administration of anti-malarial drugs to the 
whole population or to high risk groups, such as chil-
dren, results in the treatment of such infections. Most 
available anti-malarial treatments clear asexual para-
site stages but with incomplete and variable effects 
on gametocytes [8], the sexual stages responsible for 
onward transmission to the vector. Treatment of symp-
tomatic patients with SP, AQ, chloroquine (CQ), and 
piperaquine (PQ) is associated with increased gameto-
cyte carriage and or density [9–14]. Mechanisms such 
as enhancement of gametocyte production in response 
to drug-induced stress, release of sequestered gameto-
cytes and up-regulation of gametocyte production in 
response to subcurative dosage are current hypotheses 
for the emergence of post-treatment gametocytes [14, 
15], that can be infectious to the vector [12–14, 16]. 
Although the transmission potential of post-treatment 
gametocytes has been known for about 100 years [17], 
it has only recently drawn attention in relation to the 
current drive towards malaria elimination and eradi-
cation and the increased knowledge on the differential 
impact of anti-malarials on gametocyte persistence and 
infectivity [18].
SMC consists of the monthly administration of SP and 
AQ over 3 days. Only the first day of treatment (SP and 
AQ) is directly observed by trained health workers; the 
other two daily doses of AQ alone are given to care giv-
ers to be administered at home, without supervision, 
which carries the risk of poor adherence [19, 20] and 
consequently sub-optimal drug levels in children already 
infected with malaria. Considering that both SP and AQ 
increase gametocyte carriage in P. falciparum malaria 
patients [10, 12] coupled with the risk of sub-optimal 
drug levels that could trigger gametocytogenesis [15], 
SMC may increase gametocyte carriage in asymptomatic 
malaria infected children, possibly resulting in onward 
transmission to the vector since it is administered during 
the rainy season when the malaria vector is abundant.
Here, the effect of SMC on post-treatment gametocyte 




This was a prospective study conducted during the 2017 
and 2018 malaria transmission seasons in eastern Gam-
bia. Malaria transmission in The Gambia, almost exclu-
sively by P. falciparum, is highly seasonal, occurring 
mainly during the rainy season (July to October) and 
shortly after (November to December). Current control 
activities in the region include prompt diagnosis and 
treatment, vector control intervention such as indoor 
residual spraying (IRS) and insecticide-treated nets 
(ITN), and drug-based interventions such as intermittent 
preventive treatment during pregnancy (IPTp) and SMC, 
the latter implemented from 2014 onwards.
Participants selection
Potential participants were identified through the health 
and demographic surveillance system (HDSS) data base 
of villages with relatively high malaria prevalence (≥ 20%) 
according to previous surveys [21]. These were children 
24–59  months old and children 5–8  years old. The for-
mer represented the SMC group as they are eligible for 
SMC treatment; the latter were taken as comparison 
group as they do not receive SMC. Slightly older children 
were selected as a comparison group because all chil-
dren within the SMC age group would receive the SMC 
treatment during the SMC campaigns. The assumption 
was that baseline gametocyte carriage would not vary 
between the two age groups [15, 22].
Screening and enrolment
At screening, information on medical history was col-
lected and a clinical examination was performed. A dried 
blood spot (DBS) was collected via a finger prick for the 
detection of P. falciparum infection by polymerase chain 
reaction (PCR). Children with asymptomatic P. falcipa-
rum infection, without history or evidence of chronic ill-
ness and who have not received anti-malarial treatment 
in the previous 2 weeks were enrolled.
Study visits before and after SMC treatment
A visit was conducted by the study team close to the 
commencement of nation-wide SMC campaign (maxi-
mum 4 days prior). Demographic information and medi-
cal history, particularly any episode of clinical malaria or 
anti-malarial treatment since enrolment was collected. 
Axillary temperature and body weight were measured 
and recorded. Approximately 300µL of blood was col-
lected by finger prick into an ethylene diamine tetra 
acetic acid (EDTA) microtainer tube for molecular detec-
tion and quantification of P. falciparum gametocytes. 
Haemoglobin was measured with a HemoCue® pho-
tometer (Ångelholm, Sweden). Parents and care givers 
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were encouraged to participate in the upcoming SMC 
campaign and to ensure safe keeping of their SMC drug 
administration records.
The first SMC cycle was implemented by the Gambian 
National Malaria Control Programme. Briefly, a 3-day 
course of SP and AQ was administered by to all children 
aged 3 months to < 5 years in the communities. The dose 
for the first day (SP and AQ) was directly observed by the 
health worker while that of second and third days (AQ 
alone) was administered by the caregiver. An SMC distri-
bution card to document all administered doses for every 
child was issued to care givers.
Study participants were then re-visited by the study 
team approximately 2  weeks after the administration 
of the first SMC cycle. This time interval was chosen to 
allow for the emergence of gametocytes in the peripheral 
circulation [23]. History of any episode of clinical malaria 
or anti-malarial treatment since first study visit was col-
lected. Axillary temperature was measured and children 
with fever (body temperature > 37.5 ºC) were tested with 
a rapid diagnostic test (RDT) SD Bioline Malaria Ag P.F 
(Alere TM) and if positive were considered clinical malaria 
cases and treated according to national guidelines. An 
additional blood sample (300  µL) was collected by fin-
ger prick into an EDTA microtainer tube for molecular 
detection and quantification of P. falciparum gameto-
cytes. For only the children in the SMC group, informa-
tion on SMC adherence was collected as reported by care 
givers. In addition, each child’s SMC administration card 
was reviewed and administered doses as documented 
was transcribed on the study case report form and used 
to assess participants’ adherence to the treatment.
Sample processing
Blood samples collected in EDTA tubes during both 
study visits were stored in a cool box and transported to 
the laboratory within a maximum of 6 h after collection 
to maintain ribonucleic acid (RNA) stability [24]; 70  µl 
of whole blood were immediately transferred into 350 µl 
of RNAprotect Cell Reagent (Qigen, Hilden, Germany) 
and stored at -70ºC. Laboratory staff were blinded to the 
study group of each sample during analysis. Each set of a 
participant’s paired samples (i.e. sample for the same par-
ticipant collected before and after SMC administration) 
were analysed for gametocytes in the same run to avoid 
variation in laboratory procedures.
Plasmodium falciparum diagnosis was performed 
at screening by PCR. Parasite deoxyribonucleic acid 
(DNA) was extracted from DBS using the QiaAmp 
DNA minikit (Qiagen, Germany). The var gene acidic 
terminal sequence (varATS) quantitative PCR was 
used to detect multi-copy genomic sequences of infec-
tions [25]. Briefly, genomic DNA of the parasite was 
amplified in 20 µl reaction containing 1 × Taqman mas-
termix (Life Technologies, United Kingdom) and run in 
CFX96 Touch™ real-time PCR detection system (Bio-
Rad, United Kingdom). The starting quantity values 
of the parasite samples were estimated against labora-
tory grown P. falciparum 3D7 standard control (with 
medonic read of 3.74 ×  106 erythrocytes/µl and thin 
film parasitaemia of 1197 parasites/µl of blood).
For P. falciparum gametocytes detection for the sam-
ples collected before and after SMC treatment, RNA 
was extracted using Qiagen’s RNeasy® Mini kit accord-
ing to the manufacturer’s recommendations. Pfs25 
Quantitative Nucleic Acid Sequence-based Amplifica-
tion (QT-NASBA) real-time PCR was performed on the 
extracted mRNAs using the following primers (forward 
primer: 5′-GAC TGT AAA TAA ACC ATG TGG AGA -3′; 
reverse primer 5′-AAT TCT AAT ACG ACT CAC TAT 
AGG GAG AAG GCA TTT ACC GTT ACC ACA AGTTA-
3′) and PCR conditions (pre-heat at 65  °C; incubate at 
65  °C for 2  min then 41  °C for 2  min; a further 41  °C 
for 46  s incubation post enzyme introduction). Game-
tocytaemia was determined using fluorescence ampli-
fication time-points in correlation with the standard 
dilution series that was included in each run [22].
Statistical analysis
Sample size was calculated assuming baseline game-
tocyte prevalence of 50% in both the SMC and com-
parison groups [22]. A sample size of 116 evaluable 
participants in total, 58 per group, would have 80% 
power to detect a 25% difference (increase) in gameto-
cyte prevalence between groups at the 5% significance 
level.
Statistical analysis was performed using STATA soft-
ware version 16.0 (Stata Corp, College Station, Texas, 
USA). Descriptive statistics are presented for continu-
ous variables (median (IQR)) and proportions for cat-
egorical variables; point estimates are presented with 
95% confidence intervals. Analysis was restricted to 
study participants who remained asymptomatic from 
enrolment to the time of post-treatment blood sam-
pling. Gametocyte prevalence in children that received 
at least the first dose of SMC treatment (SP plus AQ) 
and in those that adhered to all 3-day doses of SMC 
treatment (SP plus AQ on day 1 and AQ alone on days 
2 and 3) was each compared with gametocyte preva-
lence in the comparison group. Difference in preva-
lence between the two groups was assessed using the 
chi-squared test. Conditional logistic regression, condi-
tional on individuals, was used to predict the odds of 
gametocyte carriage before and after treatment within 
each group.
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Ethical consideration
This study was approved by the Gambia Government/
MRC Joint Ethics Committee (SCC 1563). Children’s par-
ents or legal representative provided written informed 
consent prior to screening and study participation.
Results
A total of 1,567 children were screened for malaria infec-
tion at the beginning of two successive transmission sea-
sons (2017 and 2018); 871 children aged 2 to < 5  years 
(SMC group) and 696 aged 5 to 8  years (comparison 
group). Among these, 65 (7.5%) children in the SMC 
group and 75 (10.8%) in the comparison group had 
asymptomatic P. falciparum infection (Fig.  1). Baseline 
characteristics are as shown in Table 1. Gametocyte prev-
alence before SMC treatment was 10.7% (7/65) and 13.3% 
(10/75) in the SMC and comparison groups respectively. 
Median interval (days) between receiving SMC treatment 
and blood sampling for assessment of post-treatment 
gametocytaemia was 13  days (IQR 12, 13). At 13  days 
post-treatment, there was no difference in gametocyte 
prevalence between children in the SMC group who 
received at least the first dose of SMC treatment (SP and 
AQ) (9.4%, 5/53) and those in the comparison group 
(12.7%, 9/71), (p = 0.57). Although gametocyte preva-
lence was higher in children who adhered to all 3-day 
doses of SMC treatment (15.6%, 5/32), this was not sig-
nificantly different with gametocyte prevalence of those 
in the comparison group (p = 0.68) (Table 2). Within the 
SMC group, gametocyte carriage tended to be lower after 
SMC treatment in children that received at least the first 
dose of SMC treatment, but this was not statistically sig-
nificant (OR:0.6, 95% CI: 0.14 to 2.51, p = 0.48). Likewise, 
there was no change in odds of gametocyte carriage after 
treatment among children that adhered to all 3-day doses 
of SMC treatment (OR 1.0, 95% 0.20–4.95, p = 1.0).
Adherence to SMC treatment and occurrence of vom-
iting after treatment was assessed in 90% (48/53) of 
65 enrolled in 
SMC Group
75 enrolled in 
Comparison Group
1427 Excluded
1389  P. falciparum negative
36 Clinical malaria
2  Chronic illness
12 Excluded
9 Clinical malaria 




3 Lost to follow up
71 Included in 
primary analysis
53 Included in 
primary analysis
Fig. 1 Study Diagram
Table 1 Baseline characteristics of study participants (N = 140)
Characteristic Group
SMC (n = 65) Comparison (n = 75)
Gender (female), n (%) 31 (47.7) 35 (46.7)
Age (years), median (IQR) 3.6 (2.7–4.5) 6.5 (5.2–7.5)
Weight (kg), median (IQR) 12.8 (11.0–14.2) 18.0 (15.5–20.6)
Haemoglobin (g/dL), median 
(IQR)
10.9 (9.9–12.0) 11.1 (10.0–12.2)
Asexual parasite density (per µL), 
geometric mean (95%CI)
0.53 (0.16–1.78) 0.59 (0.15–2.36)
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children in the SMC group (Fig. 2). For all of them, the 
caregiver reported to have administered the remaining 
2  days of treatment. When this information was cross-
checked with the SMC drug administration card, only 
68.7% (33/48) and 66.6% (32/48) had the doses of the sec-
ond and third days documented on their cards, respec-
tively. A total of 27.1% (13/48) of children were reported 
to have vomited the dose for the first day shortly after 
administration while 14.6% (7/48) and 12.5% (6/48) did 
so for the doses second and third days, respectively.
Discussion
SP and AQ, the anti-malarial drugs deployed for the 
SMC intervention, are associated with marked increase 
in gametocytaemia when used to treat clinical cases of 
P. falciparum malaria [10, 12, 14]. Whether the admin-
istration of these drugs would increase prevalence of 
gametocytes among children with asymptomatic P. fal-
ciparum infections receiving SMC was investigated; no 
evidence of increased gametocyte prevalence was found.
Only a few studies have assessed the emergence of 
post-treatment gametocytes following treatment of 
asymptomatic P. falciparum infections and to our knowl-
edge, no study has addressed this question in the context 
of the SMC. Dunyo et al. [26]. in a randomized controlled 
trial (RCT) assessed whether SP increased gametocyte 
carriage following treatment of asymptomatic P. falcipa-
rum carriers that had asexual parasite densities > 20 para-
sites per micro litre but found no evidence of increased 
gametocyte prevalence or density. However, in that trial, 
microscopy was used to detect gametocytes and an 
increase in gametocytaemia may have been missed since 
emerging gametocytes typically circulate at or below 
the microscopic detection threshold [15]. In addition, 
Table 2 Differences in gametocyte carriage before and after SMC treatment
* Chi- squared test used to assess between-group difference in proportion of gametocyte carriers
∞ Conditional logistic regression used to determine within-group odds of gametocyte carriage
Measure Group p value
SMC Comparison
Percentage of gametocyte carriers before SMC treatment 7/65 (10.7%) 10/75 (13.3%) 0.64*
Percentage of gametocyte carriers after SMC treatment
 Received at least first dose of treatment 5/53 (9.4%) 9/71 (12.7%) 0.57*
 Received all 3‑day doses of treatment 5/32 (15.6%) 9/71 (12.7%) 0.68*
Odds ratio comparing gametocyte carriage before vs after SMC treatment. OR (95% CI)
 Received at least first dose of treatment 0.6 (0.14–2.51) 0.48∞














Days of SMC Treatment 
Fig. 2 Percentage of children that adhered to SMC treatment as reported by care giver (purple), as documented on the SMC distribution card 
(amber) and those that vomited administered dose shortly after administration (blue)
Page 6 of 8Ahmad et al. Malar J          (2021) 20:169 
considering the study by Dunyo et al. was a RCT, partici-
pants would have received the full treatment dose, with 
little or no risk of subcurative dosing that could trigger 
gametocyte production [27]. Conversely, sub-optimal 
dosage is probable in the context of standard SMC imple-
mentation wherein 2 out of the 3 daily doses are adminis-
tered by caregivers [19, 20] and vomiting of administered 
doses shortly after administration is common [28]. How-
ever, even with the risk of sub-optimal dosaging and 
the use of sensitive molecular methods for detection of 
gametocytes in the current study, there was no evidence 
of increased gametocyte carriage following SMC in chil-
dren that received either at least the first dose of SMC 
treatment or all 3-day doses of SMC treatment confirm-
ing findings by Dunyo et al. [26]. Of note however is that 
individuals enrolled in the current study had very low 
parasite densities (geometric mean < 1 parasite/uL), rep-
resentative of typical asymptomatic parasite carriers in 
low-endemic settings [29]. However, whilst the current 
study thus had much lower gametocyte prevalence than 
typically reported in infections with higher parasite den-
sities [29], it has the advantage of including participants 
that reflect infected individuals among the actual target 
population of SMC.
In the current study population with low parasite den-
sity and low baseline gametocyte prevalence, sensitive 
molecular gametocyte detection methods did not reveal a 
significant effect of SMC (neither increase nor decrease) 
on gametocyte carriage shortly after treatment. Perhaps 
over longer-periods of follow-up, the clearance of asexual 
parasites, the precursors of gametocytes, may result in 
lower gametocyte carriage. This result could be enhanced 
if gametocyte-clearing drugs would be added to the SMC 
regimen, reducing gametocytes persistence after treat-
ment that was also evident in the current study [18]. Such 
strategy might confer benefits for malaria transmission in 
the community.
Adherence to SMC administration as reported by car-
egivers was 100%, similar to what has been reported from 
Mali [30]. However, when comparing reported adher-
ence to the information on the SMC distribution card 
(documented adherence), the second and third doses 
were documented in only two thirds of study participants 
(Fig.  2), suggesting either caregivers’ over-reporting of 
adherence during the interviews or incomplete record-
ing. In a malaria chemoprevention trial in Uganda, drug 
levels were detectable in only 52% of cases despite car-
egivers having reported administering all assigned doses 
[20], suggesting over reporting of adherence. Similarly, a 
study on SMC uptake in Ghana concluded that up to 20% 
of children did not receive their second and third days 
treatments based on the number of tablets found at their 
homes during household visits [19]. Reported adherence 
by caregivers is, therefore, unreliable; possibly all SMC 
treatment doses should be directly observed by health 
workers or by trained village health workers, even though 
this approach could pose logistical challenges.
Vomiting occurred more often than expected [28], 27% 
of children vomited the first treatment dose; although 
the percentage was lower for the second or third dose, 
this could be due to under-reporting by the caregiv-
ers. Low tolerability may lead to low adherence, result-
ing in sub-curative doses in malaria infected individuals, 
with potential risks of selecting for drug resistant para-
sites [31], emergence of post-treatment gametocytaemia 
[15] and onward malaria transmission [32]. Sweetened 
dispersible tablets resulted in higher tolerability in Sen-
egal [33] and should perhaps be adopted as the standard 
formulation for SMC. Furthermore, provision should 
be made to compensate for vomited doses, particularly 
those administered by caregivers at home.
There are some limitations to this study that should be 
considered. Baseline gametocyte prevalence was lower 
than expected and this may have affected the power of 
the study to find a significant difference between SMC 
and comparison groups. However, there was little differ-
ence in gametocyte prevalence before and after treatment 
in the SMC group (10.7% versus 9.4%) similar to what 
was observed in the control group (13.3% versus 12.7%), 
suggesting that SMC is not associated with increased 
gametocyte carriage in the current study. Secondly, the 
fitness of gametocytes was not assessed as anti-malarial 
drugs may sterilize gametocytes before clearing them 
from circulation [34] since gametocyte transmissibil-
ity is ultimately more relevant for public health than 
gametocyte presence. Thirdly, drug concentrations were 
not measured and thus it is not possible to carry out a 
more detailed analysis on the effect of suboptimal dosing 
on post-treatment gametocytaemia. Finally, gametocy-
taemia was measured only at one time point after SMC 
treatment and this did not allow for plotting the dynam-
ics of circulating gametocytes over a longer period.
Conclusion
In this low transmission setting, there is no evidence 
that SMC administered to asymptomatic P. falciparum 
infected children is associated with higher prevalence 
of gametocytes. This therefore argues against a possible 
increase in transmission after SMC campaigns. However, 
these findings cannot be generalizable to other settings 
since factors that could determine the emergence of post-
treatment gametocytes, notably asexual parasite density 
[15] and drug resistance [35], vary across different trans-
mission settings. As SMC is delivered to millions of chil-
dren across different transmission settings of the Sahel, 
there is the need to investigate this question in other 
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settings ideally with direct assessments of transmission 
potential of gametocytes to mosquitoes.
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